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ABSTRACT 
 
In this work, four different metabolite purification approaches are investigated prior to 
Metabolomics of human HT29 colon cancer cells. Namely, methanol deproteinization, 
ultrafiltration and two solid phase extraction (SPE) methods using C18 and polymer-
based cartridges were studied. The extracts were characterized via a metabolomic 
approach based on the application of capillary electrophoresis time-of-flight mass 
spectrometry (CE-MS). CE-MS analysis time was less than 20 min per sample and 
allowed the simultaneous and reproducible analysis of more than 80 metabolites in a 
single run with a minimum consumption of sample and reagents. Metabolome analysis 
revealed in some cases important differences among the studied metabolite purification 
procedures. No significant differences were observed in the metabolite profile using 
C18 and polymer-based cartridges, or between ultrafiltration and methanol 
deproteinization. However, important differences were observed in the metabolomic 
profiles obtained from SPE and methanol deproteinization samples. These results 
demonstrate the crucial role of the metabolite purification strategy in Metabolomics 
since it can bias (and in some cases mislead) the conclusions achieved by the 
metabolomic study. 
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1. INTRODUCTION 
 
The general aim of any metabolomic study applied to a living cell, tissue or biofluid is 
to gain detailed insight of the molecular mechanisms governing the metabolic pathways. 
Like proteome, metabolome is dynamic and highly variable among cell types, 
organisms, individuals, environments, etc. Thus, one of the main challenges in 
Metabolomics is to overcome the chemical complexity, heterogeneity and wide 
dynamic concentration range of endogenous metabolites (amino acids, amines, small 
peptides, nucleic acids, carbohydrates, organic acids, vitamins, steroids, coenzymes, 
etc.) present in a biological sample. Metabolomics presents also unique challenges for 
separation and detection techniques. No single analytical methodology or platform is 
available to detect, quantify and identify all metabolites in a certain sample. Two 
analytical platforms are currently used for metabolomic analyses: MS and NMR-based 
systems. NMR, that in some cases does not require previous analyte separation (and 
requires minimal sample pre-cleaning), provides detailed information on the molecular 
structure of compounds complementary to MS-based metabolomic data, although at the 
expense of low sensitivity. Improved mass spectrometers with better sensitivity and 
superior mass accuracy and resolution are aimed to the identification and quantitation of 
complex metabolite mixtures in a single experiment. The use of high and ultra-high 
resolution mass analyzers (TOF, FTMS, Orbitrap®, etc) is essential to obtain accurate 
mass measurements for the determination of elemental compositions of metabolites and 
to carry out tentative identification based on metabolites databases. On the other hand, 
MS/MS or MS
n
 experiments, especially when product ions are accurately analyzed at 
high resolution (namely, Q-TOF, TOF-TOF, LTQ-Orbitrap®), provide useful additional 
structural information for the identification of the metabolites. These techniques either 
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standalone or combined with separation techniques (typically, LC-NMR, GC-MS, LC-
MS and CE-MS), are capable of producing complementary analytical information to get 
a more extensive metabolome coverage [1-5]. Systematic profiling/fingerprinting of as 
many metabolites as possible has gained broad interest during the last decade. CE 
technique is particularly suited for the rapid separation of ionic and polar compounds 
with very high resolution using extremely small reagents and sample volumes. 
Moreover, no pre-column derivatization of analytes is necessary. On the contrary, lower 
sensitivity and higher variability of migration times are generally obtained compared to 
LC or GC. TOF mass analyzer is preferably used in CE-MS due to its high scan speed 
high spectral acquisition rate and high mass resolution, what perfectly fits with the 
narrow peaks provided by CE. The capacity of CE-MS to analyze complex mixtures of 
metabolites in short times opens interesting possibilities in the growing Metabolomic 
area. Until today, CE-MS has successfully been applied in many metabolomic studies. 
Interesting reviews have already been published describing the potential of CE-MS in 
Metabolomics [6-9].  
In general, non-targeted metabolomics is addressed to detect as many metabolites as 
possible in a certain sample. However, at present there is not a general applicable 
sample preparation protocol to extract the whole range of endogenous metabolites 
present in a biological sample. Sample preparation is a critical step in any analytical 
method with important consequences in the final results. In order to prevent loss of 
metabolites in non-targeted Metabolomics minimal sample treatment should be carried 
out before analysis. The procedure used for metabolite extraction has to be robust and 
highly reproducible. It will depend on both the sample type and the targeted metabolites 
of interest (fingerprinting or profiling approach). Most sample extraction techniques are 
more or less selective, thus the choice of the appropriate one is very critical for 
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metabolomic studies since it can bias the final results obtained. In a non-targeted 
metabolomic work there is a clear need for the development of methods that enable a 
comprehensive characterization of the metabolome.  In this work, CE-MS was used to 
study the metabolome of human HT29 colon cancer cells. For non-targeted 
Metabolomics of biological samples deproteinization with an organic solvent is often 
carried out to avoid adsorption of proteins to the inner capillary wall and the consequent 
damage on metabolite separation and ion suppression at the ion source. In order to 
minimize sample handling and avoid extra variability to the final statistic study required 
in any non-targeted metabolomic study, several common extraction procedures (protein 
precipitation, SPE, filtration) were selected among the enormity of possibilities due to 
their simplicity, effectiveness and recognized reproducibility. Namely, four metabolite 
purification approaches were systematically compared in this work (i.e., two different 
SPE methods, protein precipitation with methanol and ultrafiltration). The metabolomic 
profiles obtained were compared based on the total number and type of extracted 
metabolites, using the information provided by CE-MS for their tentative identification. 
The results give an additional prove on the difficulty to achieve a representative 
metabolite profile in Metabolomics. 
 
2. MATERIALS AND METHODS 
 
2.1. Reagents 
 
All chemicals were of analytical reagent grade and used as received. Methanol used in 
the metabolite extraction procedure was from Sigma-Aldrich (St. Louis, MO). All 
reagents and solvents employed in the preparation of CE electrolytes and sheath liquids 
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were of MS grade: formic acid and 2-propanol were from Riedel-de Haën (Seelze, 
Germany), and water was from Scharlau (Barcelona, Spain). Amino acids from Sigma-
Aldrich were dissolved in purified water deionized by using a Milli-Q system from 
Millipore (Bedford, MA, USA), at the following concentrations: 0.58 mg/mL arginine, 
0.49 mg/mL lysine, 0.52 mg/mL histidine, 0.34 mg/mL -aminobutyric acid (GABA), 
0.39 mg/mL valine, 0.35 mg/mL serine, 0.44 mg/mL leucine, 0.40 mg/mL threonine, 
0.49 mg/mL glutamine, 0.38 mg/mL proline, 0.44 mg/mL aspartic acid and 0.09 mg/mL 
tyrosine. Tyramine, DL-methionine sulfone and 1,4-piperazinediethanesulfonic acid 
(PIPES) from Sigma-Aldrich were selected as internal standards. 
 
2.2. Samples 
 
Human colorectal adenocarcinoma HT29 cells were used in all the experiments. HT29 
cells were grown in DMEM supplemented with 5% heat-inactivated fetal calf serum, 2 
mM of L-glutamine, 50 U/ml of penicillin G and 50 µg/ml of streptomycin, at 37 ºC in 
humidified atmosphere and 5 % CO2. 
 
For sample preparation, a phosphate buffered saline (PBS) solution containing 138 mM 
sodium chloride, 2.7 mM potassium chloride and 10 mM sodium hydrogen phosphate, 
at pH 7.4, was purchased from Sigma-Aldrich. Composition of homogenization buffer 
was next: 10 mM Tris-HCl, 5 mM EDTA, 120 mM NaCl, at pH 7.4, all of them from 
Sigma-Aldrich. A protease inhibitor cocktail containing 4-(2-
aminoethyl)benzenesulfonyl fluoride (AEBSF), pepstatin A, E-64, bestatin, leupeptin, 
and aprotinin, was purchased from Sigma-Aldrich. 
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Human HT29 colon cancer cells were washed with PBS solution and centrifuged. The 
pellet was resuspended with homogenization buffer and protease inhibitor cocktail. 
Cells were disrupted with a Polytron homogenizer and centrifuged (14 min at 14000 g 
and 4ºC).  
 
Pellet (nuclear fraction) was discarded and supernatant was centrifuged for 1h at 100000 
g and 4ºC. Supernatant (cytosolic fraction) was stored at -80º C until metabolite 
purification procedure was carried out. At this temperature, enzyme activity is stopped 
and samples can safely be stored without continuing metabolic activity. The total 
protein content was determined by the Bradford method using a commercial dye reagent 
from Bio-Rad (Hercules, CA, USA) and using BSA as standard. 
 
2.3. Metabolite extraction procedures 
 
Four different metabolite extraction procedures were studied in this work: two SPE 
methods using different sorbents, protein precipitation with methanol and ultrafiltration.  
 
2.3.1. Solid-phase extraction (SPE) 
Two different sorbents were investigated, namely, Isolute C18 Endcapped cartridges 
(100 mg) from Biotage (Cardiff, Wales, UK), and Evolute
TM
 ABN columns (25 mg). 
Lower sorbent mass was selected for the last as a result of the higher capacity of the 
polymeric sorbents due to their higher specific surface area.  In both cases, activation, 
conditioning, and elution were carried out in identical conditions. Activation and 
conditioning were carried out by passing 1 mL of methanol followed by 1 mL of water 
through the cartridges. 350 µL of water were added to 150 µL of cytosolic fraction 
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obtained from the cell culture. This solution was loaded onto the column. After sample 
loading sorbent was washed with 1 mL of water-methanol (95:5, v/v). Sample elution 
was performed with 500 µL of methanol. Eluted sample was then aliquot in 100 µL 
volume. 
 
2.3.2. Protein precipitation  
For protein precipitation, 350 µL of methanol were added to 150 µL of cytosolic 
fraction sample obtained from the cell culture. The solution was incubated at -20ºC 
during 2h. After incubation the suspension was centrifuged at 20000 g and 4ºC for 5 
min. The pellet was discarded and the supernatant fraction was collected and aliquot in 
100 µL volume. 
 
2.3.3. Ultracentrifugation 
350 µL of water were added to 150 µL of cytosolic fraction sample obtained from the 
cell culture. This solution was ultrafiltrated using an Amicon Ultra 3 kDa centrifugal 
device (70 min at 14000 g and 4ºC) from Millipore (Bedford, MA, USA). Fraction with 
molecular weight lower than 3 kDa was collected and aliquot in 100 µL volume. 
 
In all cases, after metabolite purification procedures, the obtained 100 µL aliquots were 
vacuum-dried. The dried extracts were stored at -80ºC until used. Prior to CE-MS 
analysis, dried extracts were dissolved in 20 µL of water of MS grade from Scharlau. 
 
2.4. Instrumentation 
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CE analyses were carried out in a P/ACE 5500 CE apparatus from Beckman 
Instruments (Fullerton, CA, USA). The instrument was controlled by a PC running the 
System Gold software from Beckman. Uncoated fused-silica capillaries (50 m id and 
90 cm total length) from Composite Metal Services (Worcester, England) were coupled 
to MS through an orthogonal ESI interface model G1607A from Agilent Technologies 
(Palo Alto, CA, USA). Electrical contact at the electrospray needle tip was established 
via a sheath liquid. A TOF MS instrument (micrOTOF) from Bruker Daltonics 
(Bremen, Germany) was employed. The instrument was controlled by a PC running the 
micrOTOF control software from Bruker Daltonics. 
 
2.5. CE-ESI-TOF MS conditions 
 
Before first use, the separation capillary was conditioned by rinsing with 1 M NaOH for 
10 min, followed by 20 min with Milli-Q water and 5 min with the separation buffer. 
After each run, the capillary was conditioned with Milli-Q water during 4 min, followed 
by separation buffer during 4 min. Injections (53 nL of sample volume) were made at 
the anodic end using N2 pressure of 0.5 psi (34.5 mbar) for 80 s. The electrophoretic 
separation was achieved using +25 kV as running voltage at a constant temperature of 
25 ºC in a 1M formic acid BGE. Electrical contact at the electrospray needle tip was 
established via a sheath liquid based on isopropanol-water (50:50, v/v) and delivered at 
a flow rate of 0.24 mL/min by a 74900-00-05 Cole Palmer syringe pump (Vernon Hills, 
IL, USA). The mass spectrometer operated with the ESI source in the positive ion 
mode. The nebulizer and drying gas conditions were 0.4 bar N2 and 4 L/min N2, 
respectively, and maintaining the ESI chamber at 200ºC. The micrOTOF was operated 
to acquire spectra in the m/z range of 50-600 every 90 ms. The accurate mass data of the 
 10 
molecular ions were processed using the DataAnalysis 3.3 software from Bruker 
Daltonics. External and internal calibration of the TOF MS instrument was performed 
by introducing a 5 mM sodium formate solution through the separation capillary. 
Masses for the calibration of the TOF MS instrument were next: 90.9766, 158.9641, 
226.9515, 294.9389, 362.9263, 430.9138, 498.9012 and 566.8886 m/z. Each sample 
was analyzed in triplicate by CE-MS. 
 
2.6. Data processing 
 
Calculation of the elemental composition of compounds was carried out using the 
Generate Molecular Formula Editor within DataAnalysis software from Bruker 
Daltonics. Accurate m/z value and migration time from each peak was annotated. 
Redundant responses from the same ion, such as isotopic peaks, fragments, adducts, 
dimers, etc, were removed based on established m/z differences. Spike noise and low 
reliability signals (no peak-like shape) were also eliminated. For the calculation of the 
total number of the different metabolites detected by CE-MS after each extraction 
protocol, only those metabolites that repeatedly appeared in three consecutive replicates 
were considered. TOF MS provided a high mass resolution and high mass accuracy 
with errors usually below 5-10 ppm. Selected mass spectra were processed through the 
software DataAnalysis, which provided a list of possible elemental formulas by using 
the Generate-MolecularFormula Editor, which provided standard functionalities such as 
minimum/maximum elemental range, electron configuration and ring-plus double bonds 
equivalents, as well as a comparison between the theoretical and the experimental 
isotopic pattern (Sigma-Value
TM
) for increased confidence in the theoretical molecular 
formula. Tentative identification based on the obtained theoretical molecular formula 
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was carried out with different free available databases: Human Metabolome Database 
(HMDB) [10], Metlin [11], KEGG compound [12-14], and PubChem 
(http://pubchem.ncbi.nlm.nih.gov/). In cases where databases offered more than one 
possible metabolite for one molecular formula, migration time provided by 
electrophoretic separation was studied to elucidate the expected electrophoretic mobility 
of that compound at the separation pH. When available, standards were used to confirm 
metabolite identification. Metabolite relative levels were calculated from CE-MS data 
using peak areas. Freely MassTRIX web server [15] was used to map the identified 
metabolites to KEGG pathways. 
 
3. RESULTS AND DISCUSSION 
 
3.1. Sample preparation 
 
Considering the great diversity and heterogeneity of metabolites, simultaneous 
purification and analysis of all metabolites from a biological sample is still a challenge. 
Sample preparation (extraction, clean-up, concentration, etc.) for metabolomic studies 
depends on the type of sample being analyzed, the subsequent method of analysis and 
the goal of the metabolic work (whether targeted or non-targeted metabolomic study is 
going to be carried out). In many cases, sample must be pre-treated in order to eliminate 
interfering matrix constituents which can negatively affect the metabolomic results.  
 
In CE-MS, complex biological samples containing components that interact with the 
inner silica capillary surface, lead to alterations in EOF and subsequent lack of 
reproducibility between injections. More precisely, one of the main problems when 
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working with biological samples is the adsorption of proteins onto the capillary wall 
that may produce changes on EOF. On the other hand, high-salt containing sample 
could reduce efficiency due to electromigration dispersion, producing irreproducible 
injections (in case of electrokinetic injection) and migration times. Matrix effects can 
also lead to difficulties in the detection of certain compounds by MS since ESI-MS 
detection is sensitive to the presence e.g., of salts or other compounds that can 
comigrate with the analytes of interest.  
 
In this work, a lysate from human HT29 colon cancer cells with rather high salt content 
(see “Samples” section) and a total protein concentration of 0.9 mg/mL was analyzed 
using different sample preparation methodologies. Two different procedures were 
assayed to remove proteins from these samples: protein precipitation with methanol and 
deproteinization by ultrafiltration using a membrane pore size of 3 kDa. Using any of 
the mentioned procedures, only deproteinization is carried out, while salts remained in 
the final extract. On the other hand, offline SPE was also assayed for both sample 
deproteinization and desalting of samples, while additionally it can enrich the more 
retained analytes.  A wide range of chemically modified sorbent materials (silica gel or 
synthetic resins, modified or not) enable metabolite purification based on different types 
of physicochemical interactions. Reserved-phase was selected as it is widely used in 
many applications included Metabolomics. The use of polymeric sorbents is gaining 
more attention as a method for metabolite purification in non-targeted approaches. 
Thus, two different SPE sorbents were studied in this work: a classical octadecyl 
bonded endcapped silica (C18) sorbent and a polymer-based sorbent (ABN). It is 
expected that the C18 SPE retains compounds of mid to low polarity due to their polar 
interaction with the sorbent. On the other hand, ABN uses a polystyrene-divinylbenzene 
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(PS-DVB) sorbent, suitable for the extraction of a wide range of analytes (acidic, basic 
and neutral). The same extraction protocol was selected for both types of sorbents. In 
SPE loss of metabolites during sample loading and washing steps is generally 
unavoidable. In our case, washing fractions can contain small hydrophilic and charged 
metabolites that will be lost. However, together with these potentially interesting 
metabolites, interfering compounds as salts and proteins from the cytoplasm are 
expected to be also present. We decided to discard this fraction in order to avoid protein 
adsorption onto the inner capillary wall what could affect migration time reproducibility 
and metabolite signal suppression at the ESI ion source. The same cytosol sample was 
subjected to these four purification procedures. After metabolite purification, extracts 
were directly analyzed by CE-MS. 
 
3.2. CE-ESI-TOF MS method development 
 
A low pH was selected for CE-MS analysis in order to both avoid analyte adsorption 
onto the inner capillary wall and confer positive charge to the analytes to improve their 
ESI ionization yield. A BGE composed of 1 M formic acid in water at pH 1.8 was used. 
At the low pH electrolyte used in this work most amino acids, amines, nucleosides, 
small peptides, and in general, basic compounds, present overall positive charge and 
they migrate before EOF. Using these analytical conditions, CE-MS method is focused 
on cationic metabolites. However, using these electrophoretic conditions it was also 
possible to detect some acidic compounds (bearing simultaneously negative and 
positive charge in their structure), as they were carried to the MS by the residual EOF.  
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To overcome any influence from the different salt concentration of the purified samples 
on the amount injected, pressure injection was applied instead of electrokinetic injection 
being in all the cases the injected sample plug of 2.7 cm (3% of the capillary length). 
We have also taken into account that due to the complexity of the sample, during the 
CE-MS analysis it is possible that some metabolites can comigrate which disturbs the 
ionization conditions since the presence of strongly ionizable compounds will suppress 
the signal of the less ionizable ones. On the other hand, a disadvantage of CE-MS 
methods compared to LC-MS or GC-MS methods is the lower repeatability of peak 
areas. Nevertheless, good repeatability was obtained using this CE-MS method with 
%RSD values lower than 12% in the intra-day (n=5 injections) and inter-day (3 days, 
n=15 injections) repeatability study of ten different metabolites arbitrarily selected from 
the CE-MS electropherogram (peak area values and migration times are given as 
supporting information in Table S1). 
 
3.3. CE-ESI-TOF MS metabolic analysis of  human HT29 colon cancer cells 
 
3.3.1.Matrix effect 
 
After metabolite purification, the four different extracts from the HT29 colon cancer 
cells were analyzed by CE-MS. Although injected sample volume was the same in all 
the cases (3% of the capillary length), sample conductivity was expected to be different 
depending on the sample matrix due to their different salt and metabolite content. In 
order to study this effect on the CE-MS metabolite profile, the following experiments 
were carried out. First, formation of sodium formate clusters during CE-MS analysis of 
desalted (ABN extract) and non-desalted (MeOH extract) samples was observed 
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(extracted ion electropherograms, EIEs, are given in Figure S1 as supporting 
information). Basically, the results showed a small narrow peak in the desalted sample, 
while a broad band migrating from minutes 4 to 7 was observed in the non-desalted 
sample. It was also confirmed that the width of this band was proportional to the 
injected sample volume (data not shown). Typical sodium formate clusters observed 
were Na(NaCOOH)1 (90.9766 m/z), Na(NaCOOH)2 (158.9641 m/z),  Na(NaCOOH)3 
(226.9515 m/z), Na(NaCOOH)4 (294.9389 m/z), Na(NaCOOH)5 (362.9263 m/z), 
Na(NaCOOH)6 (430.9138 m/z), Na(NaCOOH)7 (498.9012 m/z), and Na(NaCOOH)8 
(566.8886 m/z), which are produced by the interaction of the sodium ion from the 
sample with the formate counterions from the BGE. This clusters formation during the 
CE separation is also expected to have some influence on the CE-MS metabolite profile 
obtained for these samples. In order to study this effect, EIEs of common metabolites 
(identical m/z) to all extracts were represented (results are given as supporting 
information in Figure S2, indicating with letters from A to G the main obtained peaks). 
As expected, a migration time shift among the different extracts (ABN, C18, MeOH and 
ultrafiltration) was obtained. This effect is dependent on the ionic strength of the 
sample, which leads to different electrical conductivities and, as a result, different 
effective electric fields inside the capillary. In addition to the observed migration time 
shift, a slight increase in plate number of the peaks for the high-ionic-strength samples 
(non-desalted MeOH and ultrafiltration extracts) was obtained. This effect is contrary to 
the expected from theory (higher electromigration dispersion in the more salty samples) 
and although at the moment we do not see a clear reason, it could be explained through 
a stacking process induced by the sodium clusters band mentioned above [16]. 
 
3.3.2. Comparison of metabolite extraction methods 
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Base peak electropherograms (BPE) from the four different metabolite extracts were 
obtained by CE-MS (they are shown as supporting information in Figure S3). 
Comparing the two extracts obtained from SPE protocols (using ABN and C18 
sorbents) it was observed that both CE-MS profiles were very similar. Namely, 80 
compounds were detected by CE-MS in the ABN extract and 71 compounds in the C18 
extract, observing that 62 of these compounds were common to both extracts. It is 
interesting to highlight at this point the better metabolite extraction power of the ABN 
sorbent at the selected SPE equilibration/elution conditions based on the higher number 
of metabolites detected (80) compared to the number obtained after C18 extraction (71). 
 
Regarding the comparison of the metabolite extraction when only sample 
deproteinization was carried out (MeOH protein precipitation vs. ultrafiltration), the 
total number of compounds identified were 83 in the MeOH extract and 74 after 
ultrafiltration. Among all these compounds, 72 were common species. This result 
demonstrates the similarity of both deproteinization procedures. It is important to 
remark that sample treatment using protein precipitation with MeOH is simpler and less 
expensive protocol than ultrafiltration. 
 
Next, selectivity of metabolite purification was studied comparing the best two 
protocols (which allowed the detection of a higher number of metabolites), namely, 
deproteinization and desalting using ABN cartridge, and MeOH deproteinization. After 
mass spectra analysis, important differences in terms of the selectivity of metabolite 
extraction were observed. In Figure 1, the EIEs of the compounds with different 
migration times observed in both extracts (ABN and methanolic extract) are 
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represented. Taking into account both extracts, a total number of 115 different 
metabolites were detected, of which 80 metabolites were found in ABN, 83 in MeOH 
extracts, being 48 compounds common to both extracts. In Figure 2, a bar plot of peak 
areas of the common metabolites extracted using the ABN cartridge or MeOH protein 
precipitation is presented. On the top of each column the metabolite (or peak) number 
assigned in Figure 1 and Table 1 is indicated. From this group of 48 compounds, 
statistically significant higher intensities (after ANOVA at 5% significance level) were 
observed for 22 peaks (namely, 1, 8, 22, 26, 33, 34, 50, 51, 53, 56, 65, 67, 72, 76, 77, 
83, 86, 88, 90, 91, 96 and 97) when ABN extraction was used. On the other hand, 
among the common 48 compounds, only 8 showed a significantly higher (p<0.05) 
signal in the MeOH extract (peaks 17, 30, 52, 55, 57, 79, 84 and 110), what seems to 
indicate some clear bias in the quantitative extraction of these compounds depending on 
the purification protocol applied. Regarding the non-common compounds, 32 
metabolites were detected using SPE with the ABN column, and 35 metabolites could 
only be detected by sample deproteinization with MeOH. This result is indicative of an 
important bias in the quantitative metabolomic analysis induced by the sample 
preparation step, as well as in the type and nature of the identified metabolites as will be 
corroborated below. The reproducibility obtained after metabolite purification using 
ABN or MeOH was similar. Namely, RSD values for peak areas were lower than 12% 
and 13% after ABN and MeOH extraction, respectively. These values were calculated 
for metabolites 56, 72 and 88 in three different extracts obtained under the same 
conditions using ABN or MeOH purification and analyzed in triplicate in the same day 
(total n=9). This information is given as supporting information in Table S2. 
 
3.3.3. Metabolite identification 
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In Table 1, a list of detected compounds and tentative identification using both ABN 
and MeOH purification protocols is presented. The TOF-MS analyzer used in this work 
was operated to acquire spectra in the range of 50-600 m/z. Most of the observed ions 
were single protonated ions (M+H
+
) and few of the species were detected as doubly 
charged (see Table 1). A total number of 115 different metabolites were detected with 
molecular masses from 90.0 to 777.2 Da. Among them, 45 compounds could not be 
identified since each one of the obtained m/z values was associated with more than 10 
molecular formulas (considering an error lower than 10 ppm). In other cases a 
molecular formula was proposed but no endogenous metabolite could be found in 
metabolite databases. In certain cases, two or three metabolites were associated to a 
single molecular formula (metabolites 21, 29, 32, 38, 39, 52, 57, 64, 66, 70, 85, 108). In 
these cases, confirmation of identification was carried out based on their expected 
electrophoretic mobility at the separation pH and/or, when available, using standards. 
Thus, identification of histidine (peak 15), arginine (peak 20), lysine (peak 21), GABA 
(peak 29), valine (peak 52), serine (peak 53), leucine (or isoleucine) (peak 57), 
threonine (peak 64), glutamine (peak 66), proline (peak 70), tyrosine (peak 78) and 
aspartic acid (peak 85) was corroborated mixing the corresponding metabolite extract 
with standards solution. In certain cases, expected electrophoretic mobility was not 
enough information, and standard compound was not available in our laboratory. Thus, 
more than one metabolite had to be associated to a unique molecular formula. As an 
example, peak 32 with m/z value of 152,1072 and formula C9H13NO was tentatively 
identified as N-methyltyramine and N-methylphenylethanolamine. Similar situation was 
founded for peaks 29, 38, 39 and 108 (see Table 1). 
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It is interesting to mention that among all amino acids detected (12), only histidine, 
valine, serine and leucine (or isoleucine) were observed in both metabolite extracts 
obtained after MeOH deproteinization or ABN purification. A more hydrophobic amino 
acid derivative as lipoillysine was only found in the ABN extract what seems to indicate 
some trend (although not definitive) to low polarity amino acids when ABN cartridges 
are used. The rest of amino acids (arginine, lysine, GABA, threonine, glutamine, 
proline, tyrosine and aspartic acid) were only detected when methanol was used for 
purification. Other identified endogenous metabolites with high number of polar groups 
in their structure, such as gluthathione disulfide (peak 92), iminodiacetate (peak 103), 
AMP nucleotide (peak 108), and phosphocreatine (peak 115), could only be detected in 
the methanolic extract. Finally, most metabolites with phosphorus, sulphur or at least 
four oxygen atoms presented the highest migration times in good agreement with their 
expected electrophoretic mobilities at the separation pH. Moreover, a good number of 
tripeptides (peaks 8, 12, 14, 60, 61, 65, 74, 88 and 91) were proposed. Due to the lack of 
information from MS/MS spectra in this work, only amino acidic composition is 
indicated for each peptide. 
 
It was also observed the presence of three exogenous compounds, namely 4-(2-
Aminoethyl) benzenesulfonyl fluoride hydrochloride (AEBSF), bestatin and N-[N-(L-3-
trans-carboxyirane-2-carbonyl)-L-leucyl]-agmatine (E-64) coming from the protease 
inhibitor cocktail used during cytosolic content isolation protocol. This finding is an 
additional demonstration on the consistency of these results. 
 
In resume, from the 115 detected compounds, 44 metabolites were tentatively identified 
and classified in several groups. Most abundant compounds were amino acid and 
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polypeptides, although other compounds such as lipoic acid derivatives, steroid 
derivatives, carbohydrates derivatives, amino alcohol, amino acid phosphates, 
nucleosides, quaternary amines, pterins, acyl phosphates and nucleotides, were also 
found. Identified metabolites were automatically mapped to KEGG pathways using 
MassTrix. Among all tentatively identified compounds, 20 of them were related to the 
following metabolic pathways: (1) glycan biosynthesis and metabolism, (2) organismal 
systems: excretory system, (3) neuroactive ligand-receptor interaction, (4) carbohydrate 
metabolism, (5) lipid metabolism, (6) nucleotide metabolism, (7) energy metabolism, 
(8) metabolism of cofactors and vitamins, (9) environmental information processing, 
(10) genetic information processing and (11) amino acid metabolism. A particular case 
was creatine (peak 38), detected only in the methanolic extract, that was associated to 
more than 100 metabolic pathways. In Figure 3, a bar plot representing the number of 
metabolites associated to the above mentioned metabolic pathways, is presented. 
Information from both ABN and methanolic extracts is presented in order to show a 
general overview of the metabolic information obtained depending on the selected 
metabolite purification approach. As can be seen in Figure 3, metabolites from both 
ABN and methanolic extracts were associated to nine metabolic pathways (numbered 
from 3 to 11), although the number of metabolites was different in practically all cases. 
For instance, in the metabolic pathway number 11 of Figure 3, 16 metabolites were 
found in methanolic extract and only 5 in ABN extract. As a general trend in this study, 
the use of methanol deproteinization brought about a higher number of metabolites 
associated to known metabolic pathways and, therefore, wider metabolomic information 
could be obtained. 
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4. CONCLUDING REMARKS 
 
Sample preparation is frequently underestimated in most metabolomic works. We have 
unequivocally demonstrated in this work that the composition and the quantity of 
metabolites detected depend to a large extent on the sample preparation step. Metabolite 
purification through methanol extraction showed good potential for metabolome 
characterization of human HT29 colon cancer cells, while the SPE results showed good 
extraction efficiency with different selectivity compared to protein methanol 
precipitation and ultrafiltration. However, SPE is usually considered more attractive for 
the on-line coupling extraction with CE-MS since sample manipulation can be 
simplified overall analytical procedure, allowing automatization of the sample 
treatment, separation and detection in metabolomic studies. Selection of an appropriate 
sample treatment for a certain metabolomic study is, therefore, crucial. These results 
show the important influence from the metabolite purification strategy since it can bias 
and in some cases mislead the conclusions achieved by Metabolomics. So, the question 
remains: is Metabolomics approachable?. Clearly, to achieve a whole Metabolomics 
study of a biological system is still challenging at least based on the current available 
methodologies. A possible solution could be the use of multiple sample preparation 
procedures to cover a broad (and, therefore, more informative and representative) range 
of metabolites and concentrations. 
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FIGURE LEGENDS 
 
Figure 1. CE-MS extracted ion electropherograms of the 115 m/z values detected in 
metabolite extracts obtained from SPE (ABN cartridge) or methanol deproteinization. 
CE-MS conditions are described in the text. 
 
Figure 2. Representation of bar plot of peak areas of the common metabolites extracted 
using SPE (ABN cartridge) or protein precipitation with methanol. Metabolite number 
is assigned in Figure 1 and Table 1. 
 
Figure 3. Number of compounds identified in some metabolic pathways in metabolite 
extracts obtained from SPE (ABN cartridge) or methanol deproteinization. 
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Table 1. Tentative identification of metabolites after CE-MS analysis. 
No. ABN MeOH m/z z Sigma
TM
 
Error 
(ppm) 
Formula Tentative identification Classification Database KEGG pathway 
1 YES YES 145,0167 1 0,156 -2,9 C5H5ClN2O     
2 YES YES 90,9768 1 0,001 0,2 CNa2O2 Disodium formate Inorganic salt   
3 YES YES 272,9392 1 ‹0.1 ‹10 -
a)
     
4 YES YES 189,0972 1 0,102 2,4 C6H12N4O3 X
 b)
    
5 NO YES 225,1431 1  +10      
6 YES NO 427,2860 1 ‹0.1 ‹10 -     
7 YES NO 134,9864 1 0,025 -4,1 C2H2N2O3S X    
8 YES YES 321,1257 1 0,026 -9,2 C11H20N4O5S1 Tripeptide (G,N,M; A,Q,C) Polypeptide METLIN  
9 NO YES 116,0837 1  +10      
10 YES NO 335,1442 1 0,026 4,6 C14H26N2O3S2 Lipoyllysine Lipoic acid derivative HMDB12996  
11 YES NO 363,1763 1 0,04 3,6 C16H22N6O4 Thyrotropin-releasing factor Polypeptide HMDB05763 hsa04080 
12 YES NO 175,0855 2 0,020 4,6 C12H24N6O4S1 Tripeptide (C,R,A) Polypeptide METLIN  
13 YES NO 377,1924 1 0,024 9,1 C21H28O6 18-Oxocortisol Steroid derivative HMDB00332  
14 YES NO 203,1115 2 0,027 -6,2 C20H28N4O5 Tripeptide (I/L, W, S; W, T, V) Polypeptide METLIN  
15 YES YES 156,0767 1 0,175 0,7 C6H9N3O2 Histidine Amino acid HMDB00177
 c)
 
hsa00340, hsa00410, 
hsa02010, hsa00970, 
16 YES NO 211,0943 1 ‹0.1 ‹10 -     
17 YES YES 128,0818 1 0,006 -0,5 C5H9N3O X    
18 YES NO 470,1381 1 ‹0.1 ‹10 -     
19 YES NO 242,5777 2 ‹0.1 ‹10 -     
20 NO YES 175,1193 1 0,046 -1,9 C6H14N4O2 Arginine Amino acid HMDB03416
c)
 
hsa00472, hsa00330, 
hsa02010, hsa00970 
21 NO YES 147,1133 1 0,042 -3,5 C6H14N2O2 Lysine (+2 metabolites) Amino acid HMDB00182
 c)
 
hsa00780, hsa00310, 
hsa00300, hsa02010, 
hsa00970 
22 YES YES 504,1611 1 ‹0.1 ‹10 -     
23 YES NO 546,2033 1 0,088 -0,9 C20H35NO16 Lacto-N-triaose Carbohydrate HMDB06592  
24 YES NO 194,0089 1 ‹0.1 ‹10 -     
25 YES NO 532,1955 1 ‹0.1 ‹10 -     
26 YES YES 160,1078 1 0,003 1,6 C6H13N3O2 X    
27 NO YES 526,1438 1 ‹0.1 ‹10 -     
28 NO YES 510,1496 1 ‹0.1 ‹10 -     
I.S. YES YES 138,0917 1 0,004 -2,9 C8H11NO Tyramine    
29 NO YES 104,0704 1 0,005 2,2 C4H9NO2 Aminobutyric acid(+7 metabolites) Amino acid HMDB00112
 c)
  
30 YES YES 204,0484 1 0,004 2,4 C8H10FNO2S AEBSF (protease inhibitor)  CID 1701  
31 YES NO 489,4360 1 ‹0.1 ‹10 -     
32 YES YES 152,1072 1 0,058 -1,1 C9H13NO 
N-Methyltyramine 
N-Methylphenylethanolamine 
Amino alcohol 
Amino alcohol 
HMDB03633 
HMDB01387 
hsa00350 
 
33 YES YES 218,0661 1 0,020 -0,6 C8H11NO6 
2-(Acetamidomethylidene)-3-
(hydroxymethyl)butanedioc acid 
   
34 YES YES 130,1592 1 0,007 -1,3 C8H19N X    
35 YES NO 228,1006 1 ‹0.1 ‹10 -     
36 YES NO 230,0851 1 ‹0.1 ‹10 -     
37 YES NO 244,0950 1 0,574 -9,0 C9H13N3O5 Cytidine Nucleoside HMDB00089 hsa00240 
38 NO YES 132,0771 1 0,007 -2,6 C4H9N3O2 
Creatine  
Beta-Guanidinopropionic acid 
 
HMDB00064 
HMDB13222 
hsa00260, hsa00330 
 
39 NO YES 264,0527 1 0,026 3,4 C9H13NO6S 
Epinephrine sulfate 
N-acetyl-S-(3-oxo-3-carboxy-n-
propyl)cysteine 
 
HMDB01876 
HMDB02194 
 
40 YES YES 303,6563 2 ‹0.1 ‹10 -     
41 YES NO 188,2022 1 0,014 -1,8 C11H25NO  X    
42 YES NO 174,1836 1 0,005 -5,6 C10H23NO  X    
43 NO YES 218,1380 1 0,033 3,1 C10H19NO4 Propionylcarnitine Quaternary amine HMDB00824  
44 YES YES 192,1607 1 0,03 -1,4 C9H21NO3  X      
45 YES NO 271,1241 2 ‹0.1 ‹10 -     
46 YES YES 548,1568 1 ‹0.1 ‹10 -     
47 YES YES 200,2367 1 0,007 2,7 C13H29N Octamylamine  CID 10406  
48 YES NO 214,2522 1 0,008 3,5 C14H31N X    
49 YES YES 218,2083 1 0,133 2,2 C8H23N7 X    
50 YES YES 287,1039 1 0,010 6,4 C8H14N8O2S X    
51 YES YES 230,2475 1 0,02 1,7 C14H31NO X      
52 YES YES 118,0868 1 0,005 -4,4 C5H11NO2 Valine (+ 3 metabolites) Amino acid HMDB00883
 c)
 
hsa00640, hsa00770, 
hsa00280, hsa00290, 
hsa00970 
53 YES YES 106,0499 1 0,021 0,2 C3H7NO3 Serine Amino acid HMDB00187
 c)
 
hsa00600, hsa00920, 
hsa00460, hsa00270, 
hsa00260, hsa00970 
54 NO YES 301,1172 1 ‹0.1 ‹10 -     
55 YES YES 387,0834 1 0,019 2,3 C12H10N12O2S X    
56 YES YES 349,1170 1 0,018 -7,8 C15H16N4O6 Riboflavin reduced Pterin HMDB01557  
57 YES YES 132,1015 1 0,004 2,8 C6H13NO2 Leucine or Ilsoleucine  (+ 3 metabolites) Amino acid 
HMDB00687, 
HMDB00172
 c)
 
hsa00280, hsa00290, 
hsa00970 
58 NO YES 299,1036 1 ‹0.1 ‹10 -     
59 YES NO 335,1377 1 0,024 1,9 C12H22N4O5S Tripeptide (V, N, C; M, Q, G; A, M, N) Polypeptide METLIN  
60 YES NO 429,1509 1 ‹0.1 ‹10 -     
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61 YES NO 363,1681 1 0,023 4,5 C14H26N4O5S1 Tripeptide (I/L,C,Q; N,V,M) Polypeptide METLIN  
62 YES NO 258,2788 1 0,011 1,3 C16H35NO X    
63 YES NO 288,2892 1 0,037 1,9 C17H37NO2 X    
64 NO YES 120,0659 1 0,737 -3,5 C4H9NO3 Threonine  (+ 2 metabolites) Amino acid HMDB00167
 c)
 
hsa00860, hsa00290, 
hsa00260, hsa00970 
65 YES YES 291,1682 1 0,030 -6,4 C11H22N4O5 Tripeptide (G,S,K) Polypeptide METLIN  
66 NO YES 147,0758 1 0,006 4,1 C5H10N2O3 Glutamine  (+ 2 metabolites) Amino acid HMDB00641 
c)
 
hsa00240, hsa04964, 
hsa00230, hsa00471, 
hsa00910, hsa00250, 
hsa00330, hsa02010, 
hsa00970 
67 YES YES 323,1961 1 0,018 1,3 C17H26N2O4 X    
68 YES NO 305,1858 1 0,012 5,9 C15H29O4P Dolichol phosphate Acyl phosphate HMDB06353 hsa00510 
69 YES NO 351,2254 1 ‹0.1 ‹10 -     
70 NO YES 116,0714 1 0,0029 -6,9 C5H9NO2 Proline (+ 1 metabolite) Amino acid HMDB00162 
c)
 
hsa00330, hsa02010, 
hsa00970 
71 YES YES 309,1806 1 0,009 0,9 C16H24N2O4 Bestatin (protease inhibitor)  CID 72172  
72 YES YES 323,1964 1 0,110 0,6 C17H26N2O4 X    
73 NO YES 365,0834 1 ‹0.1 ‹10 -     
74 YES YES 327,1417 1 0,1885 -2,2 C12H18N6O5 Tripeptide (N,H,G) Polypeptide METLIN  
75 YES NO 408,1959  ‹0.1 ‹10 -     
76 YES YES 380,6276 2 ‹0.1 ‹10 -     
77 YES YES 474,1998 1 ‹0.1 ‹10 -     
78 NO YES 182,0819 1 0,035 -4,2 C9H11NO3 Tyrosine Amino acid HMDB00158
 c)
 
hsa00130, hsa00360, 
hsa00400, hsa00730, 
hsa00410, hsa00970 
79 YES YES 570,1186 1 ‹0.1 ‹10 -     
80 YES YES 397,2848 1 ‹0.1 ‹10 -     
81 YES NO 584,1268 1 ‹0.1 ‹10 -     
82 NO YES 191,1025 1 0,005 0,6 C7H14N2O4 Diaminopimelic acid Amino acid HMDB01370 hsa00300 
83 YES YES 474,1990 1 ‹0.1 ‹10 -     
84 YES YES 413,2810 1 ‹0.1 ‹10 -     
85 NO YES 134,0451 1 0,0055 -2,5 C4H7NO4 
Aspartic acid 
(+ 1 metabolite) 
Amino acid HMDB00191 
c)
 
hsa00760, hsa04080, 
hsa00340, hsa00410, 
hsa00460, hsa00770, 
hsa00910, hsa00250, 
hsa00270, hsa00300, 
hsa00260, hsa00330, 
hsa02010, hsa00970 
86 YES YES 429,3182 1 0,004 0,3 C20H40N6O4 X    
87 YES YES 445,3136 1 ‹0.1 ‹10 -     
88 YES YES 492,2153 1 0,028 -4,9 C27H29N3O6 Tripeptide (Y,Y,F) Polypeptide METLIN  
89 NO YES 510,1815 1 0,159 2,1 C21H36NO9S2 X    
90 YES YES 443,2985 1 ‹0.1 ‹10 -     
I.S. NO YES 182.0478 1 0,005 1,9 C5H11NO4S Methionine sulfone    
91 YES YES 394,1854 1 0,106 -6,3 C16H31N3O4S2 Tripeptide (I/L,M,M) Polypeptide METLIN  
92 NO YES 307,0835 2 0,016 -0,8 C20H32N6O12S2 Glutathione disulfide Polypeptide HMDB03337 hsa0480 
93 NO YES 400,1326 1 0,003 -3,8 C11H21N5O11 X    
94 NO YES 396,1639 1 ‹0.1 ‹10 -     
95 NO YES 290,1019 2 ‹0.1 ‹10 -     
96 YES YES 298,1022 2 ‹0.1 ‹10 -     
97 YES YES 389,6241 2 ‹0.1 ‹10 -     
98 YES YES 381,6264 2 ‹0.1 ‹10 -     
99 NO YES 326,6199 2 ‹0.1 ‹10 -     
100 YES YES 358,2086 1 0,024 -0,3 C15H27N5O5 E-64  (protease inhibitor)  CID 123985  
101 NO YES 258,2770 1  +10      
102 NO YES 326,6191 1  +10      
103 NO YES 134,0455 1 0,017 -5,6 C4H7NO4 Iminodiacetate    
104 NO YES 217,0822 1 ‹0.1 ‹10 -     
105 NO YES 186,0584 1 0,005 -0,60 C8H11NO2S X    
106 YES YES 369,0941 1 ‹0.1 ‹10 -     
107 YES YES 552,1293 1 ‹0.1 ‹10 -     
108 NO YES 348,0731 1 0,012 -7,8 C10H14N5O7P 
2'-Deoxyguanosine 5'-monophosphate 
Adenosine 2'-phosphate 
Adenosine 5’-phosphate 
Nucleotide 
HMDB01044 
HMDB11617 
HMDB00045 
 
 
hsa01100 
d)
 
109 NO YES 184,0743 1 0,003 -9,6 C5H14NO4P Phosphocholine  METLIN  
110 YES YES 478,1304 1 ‹0.1 ‹10 -     
111 YES NO 516,0779 1 ‹0.1 ‹10 -     
112 YES NO 529,3531 1 ‹0.1 ‹10 -     
113 NO YES 293,0966 1 ‹0.1 ‹10 -     
114 NO YES 504,1329 1 ‹0.1 ‹10 -     
115 NO YES 212,0426 1 0,034 2,1 C4H10N3O5P Phosphocreatine Amino acid phosphate HMDB01511 hsa01100 
d)
 
I.S. YES YES 303.0607 1 0,006 2,7 C8H18N2O6S2 PIPES    
a) More than 10 molecular formulas were assigned to the obtained m/z value. 
b) No endogenous metabolite can be associated to the assigned molecular formula 
c) Tentative identification was confirmed with commercial standards 
d) hsa01100 code includes more than 20 metabolic pathways 
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Supporting information 
 
Figure S1. CE-MS extracted ion electropherograms of the sodium formate clusters 
obtained from ABN extract (upper electropherogram) and methanolic extract (lower 
electropherogram). Characteristic mass spectra are shown in the lower panel. CE-MS 
conditions are described in “CE-ESI-TOF MS conditions” section. 
 
Figure S2. CE-MS extracted ion electropherograms of the 43 m/z ions common to all 
extracts. Seven peaks (from A to G) are marked in the electropherograms for a better 
comparison of the purification strategies. Peak A: 122.08 m/z, peak B: 204.05 m/z, peak 
C: 387.08 m/z, peak D: 291.17 m/z, peak E: 309.18 m/z, F: 413.29 m/z, and G: 182.05 
m/z. CE-MS conditions are described in “CE-ESI-TOF MS conditions” section. 
 
Figure S3. Base peak electropherograms of the cytosolic fraction from colon cancer cell 
culture after four different metabolite extraction procedures. CE-MS conditions are 
described in “CE-ESI-TOF MS conditions” section. 
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Table S1. Peak areas, migration times and RSD values for ten different metabolites detected by CE-MS after ABN extraction in three different days. CE-MS 
conditions are described in section 2.5. 
DAY 1 R1 R2 R3 R4 R5 tmig Area 
Metabolite
No. 
t mig A t mig A t mig A t mig A t mig A Med SD RSD Med SD RSD 
15 6.55 8265 6.62 7654 6.75 8038 6.85 7652 6.97 8017 6.75 0.17 2.5 7925 267 3.4 
22 7.05 78569 7.15 72086 7.29 74241 7.37 75540 7.50 82332 7.27 0.18 2.4 76554 3993 5.2 
32 7.57 725663 7.69 702632 7.86 767788 7.95 715422 8.09 763530 7.83 0.21 2.6 735007 29186 4.0 
40 8.16 14532 8.22 14628 8.45 15550 8.55 15201 8.71 14123 8.42 0.23 2.7 14807 566 3.8 
46 8.70 4205 8.77 3955 8.93 4475 9.01 4503 9.19 4355 8.92 0.20 2.2 4299 225 5.2 
56 9.40 110523 9.46 116568 9.65 112865 9.76 102568 9.94 109936 9.64 0.22 2.3 110492 5139 4.7 
72 10.35 2685020 10.41 2638364 10.58 2890925 10.71 2769980 10.88 2432013 10.59 0.22 2.1 2683260 170139 6.3 
88 11.15 130982 11.23 127066 11.39 141619 11.52 146230 11.68 125969 11.39 0.21 1.9 134373 9064 6.7 
91 11.51 2664120 11.70 2874057 11.79 2859792 11.89 2669031 12.16 2508991 11.81 0.24 2.0 2715198 152811 5.6 
106 16.11 335642 17.53 308625 17.40 381204 16.90 370219 17.91 359821 17.17 0.70 4.0 351102 29116 8.3 
DAY 2 R1 R2 R3 R4 R5 tmig Area 
Metabolite
No. 
t mig A t mig A t mig A t mig A t mig A Med SD RSD Med SD RSD 
15 6.12 8803 6.22 9288 6.32 8166 6.44 8456 6.69 9113 6.36 0.22 3.5 8765 461 5.3 
22 6.65 65684 6.63 68612 6.79 59917 6.93 62464 7.21 64121 6.84 0.24 3.5 64160 3280 5.1 
32 7.24 700996 7.17 741936 7.35 643436 7.55 675458 7.85 693140 7.43 0.27 3.7 690993 36065 5.2 
40 7.79 17698 7.62 16398 7.86 14854 8.08 16584 8.40 16918 7.95 0.30 3.8 16490 1041 6.3 
46 8.28 4809 8.00 5034 8.29 4350 8.54 4583 8.87 4664 8.40 0.33 3.9 4688 255 5.4 
56 8.90 95684 8.52 98724 8.85 85245 9.14 89878 9.49 91184 8.98 0.36 4.0 92143 5232 5.7 
72 9.75 2515102 9.26 2587314 9.65 2220188 9.97 2355491 10.33 2384463 9.79 0.40 4.0 2412512 143272 5.9 
88 10.42 158847 9.82 167502 10.28 143237 10.63 152494 11.00 153825 10.43 0.44 4.2 155181 8902 5.7 
91 10.86 2375011 10.19 2488590 10.70 2112414 11.05 2265612 11.43 2278126 10.85 0.46 4.2 2303951 139610 6.1 
106 14.82 434226 13.92 452856 14.65 379092 15.10 412280 15.58 410724 14.81 0.61 4.1 417836 27738 6.6 
DAY 3 R1 R2 R3 R4 R5 tmig Area 
Metabolite
No. 
t mig A t mig A t mig A t mig A t mig A Med SD RSD Med SD RSD 
15 5.85 9566 5.92 10005 6.02 9259 6.08 10082 6.25 9577 6.02 0.15 2.6 9698 342 3.5 
22 6.33 63332 6.35 59379 6.43 56421 6.50 63777 6.67 59206 6.46 0.14 2.1 60423 3094 5.1 
32 6.82 829796 6.87 880844 6.98 781408 7.00 846435 7.24 808650 6.98 0.16 2.3 829427 37652 4.5 
40 7.24 16104 7.34 17867 7.42 17621 7.44 18864 7.69 17972 7.43 0.17 2.3 17686 1001 5.7 
46 7.58 4991 7.74 4961 7.77 4492 7.80 5002 8.07 4853 7.79 0.18 2.3 4860 214 4.4 
56 8.09 86017 8.31 85230 8.32 94152 8.32 82006 8.62 86626 8.33 0.19 2.3 86806 4476 5.2 
72 8.72 2179522 9.07 2305314 8.99 2083717 8.96 2208366 9.35 2097898 9.02 0.23 2.5 2174963 89990 4.1 
88 9.27 155015 9.70 158715 9.57 175790 9.52 177548 9.94 166363 9.60 0.25 2.6 166686 10009 6.0 
91 9.59 2165933 10.05 2021198 9.89 2326637 9.84 2040365 10.30 2149446 9.93 0.26 2.6 2140716 122100 5.7 
106 13.67 402900 14.48 437380 14.17 481275 13.92 454391 14.71 453070 14.19 0.42 2.9 445803 28707 6.4 
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Table S2. Overall reproducibility (sample preparation + CE-MS analysis) given as peak areas and RSD values for metabolites 56, 72 and 88 determined in 
three ABN and MeOH extracts obtained under the same conditions and analyzed in triplicate by CE-MS (total n=9).  
 
ABN 
No. m/z CE-MS Rep. 
Peak area 
(Treatment 1) 
Peak area 
(Treatment 2) 
Peak area 
(Treatment 3) 
Mean SD % RSD 
56 349.117 
R1 105065 101583 108973 
104504 6462 6 R2 107374 92001 113464 
R3 104004 98574 109500 
72 323.1964 
R1 2296328 2359709 2465852 
2395546 154976 6 R2 2424419 2135371 2608870 
R3 2389613 2269479 2610277 
88 492.2153 
R1 130842 154736 162406 
156981 18451 12 R2 141178 154733 175277 
R3 139635 164498 189523 
MeOH 
No. m/z CE-MS Rep. 
Peak area 
(Treatment 1) 
Peak area 
(Treatment 2) 
Peak area 
(Treatment 3) 
Mean SD % RSD 
56 349.117 
R1 23018 26045 24145 
24658 1852 8 R2 21283 27317 24878 
R3 23553 25745 25939 
72 323.1964 
R1 10958 10716 12283 
10949 1129 10 R2 9939 10175 11909 
R3 9862 9879 12819 
88 492.2153 
R1 130118 102388 95395 
110122 14524 13 R2 118505 96908 102439 
R3 135152 101220 108975 
 
 
